Jean H. Hoffman-Censits, MD, presented “Immune Checkpoint Inhibitors: Combination Therapy” at the 6th International Bladder Cancer Update on November 19, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Hoffman-Censits, Jean H. “Immune Checkpoint Inhibitors: Combination Therapy.” November 2022. Accessed Aug 2024. https://grandroundsinurology.com/immune-checkpoint-inhibitors-combination-therapy/
Immune Checkpoint Inhibitors: Combination Therapy – Summary
Dr. Jean H. Hoffman-Censits delves into the evolving landscape of bladder cancer treatment, focusing on the synergy between immune checkpoint inhibitors and other therapeutic modalities. She discusses the mechanisms by which immune checkpoint inhibitors enhance the body’s immune response against cancer cells. She emphasizes the groundbreaking potential of these inhibitors when used in combination with traditional treatments such as chemotherapy, radiation therapy, and novel targeted therapies. Through detailed analysis and clinical trial data, Dr. Hoffman-Censits demonstrates how these combinations can lead to improved patient outcomes, including higher response rates and prolonged survival.
Dr. Hoffman-Censits presents compelling evidence from studies involving PD-1 and PD-L1 inhibitors combined with other agents, revealing significant advancements in tumor regression and disease control. She discusses the strategic considerations in selecting appropriate combination therapies based on patient-specific factors, including genetic markers and tumor characteristics.
Dr. Hoffman-Censits also addresses the challenges and future directions in the field, acknowledging the complexities of managing immune-related adverse events and the need for ongoing research to optimize treatment protocols. Her presentation underscores the importance of a multidisciplinary approach in the management of bladder cancer, advocating for collaboration among oncologists, researchers, and healthcare professionals to refine and advance combination therapy strategies.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Jean Hoffman-Censits, MD, is Associate Professor of Medical Oncology and Urology at The Johns Hopkins University School of Medicine. Dr. Hoffman-Censits earned her medical degree at The Sidney Kimmel Medical College at Thomas Jefferson University, where she completed her internal medicine residency and chief residency. She completed her oncology training at Fox Chase Cancer Center, then returned to Jefferson as a genitourinary (GU) medical oncologist, leading their multidisciplinary GU oncology clinic. She joined the Johns Hopkins Greenberg Bladder Cancer Institute in 2018 as the co-leader of the Women’s Bladder Cancer Program and Upper Tract Urothelial Cancer (UTUC) Multidisciplinary Clinic.
